Tech

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

WNVis a positive single-stranded RNA flavivirus of about 11 kb. It primarily infe...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients during the course of chemotherapy. It is difficult to imagine medical...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX NewsNetwork) -- Generex Biotechnology Corporation (Nasdaq:GNBT), theleader in drug delivery for metabolic diseases through the innerlining of the mouth, announced today that it will be making threeposter presentations at the 46th Annual Meeting of the EuropeanSociety of Pediatric Endocrinology in Helsinki, Finland June 27 --30, 200...

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today that it will present at theC.E. Unterberg, Towbin Emerging Growth Opportunities Conferenceheld at the Mandarin Oriental Hotel in New York City from July10-12, 2007. The Company's presentation is scheduled for 2:00 p.m.(EDT) on Tuesday, July 10, 2007. The presentation will be webcastlive and...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase I and PhaseII data on the Company's prostate cancer drug candidate CB7630(abiraterone acetate) were presented at the European Society forMedical Oncology (ESMO) Conference, which is currently taking placein Lugano, Switzerland. The data were presented in two oral andposter...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, presentedposter presentations at the 5th International Society for Stem CellResearch Annual Meeting (ISSCR) in Cairns, Queensland, Australiafrom June 17-20 and at the 13th Annual Meeting of the InternationalSociety for Cel...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line without destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI)has presented pre-clinical data for the 57-57 project at the 8thWorld Congress on Inflammation (<a target="_blank" href="http://www.inflammation2007.dk/">www.inflammation2007.dk ) heldin Copenhagen June 16-20*. "The results strengthen the further clinical development of57-57 for the treatment of SLE and show the possib...

New Positive Pre-clinical Data for Active Biotech's RA Project I-3D

LUND, June 15, 2007-Active Biotech (OMX Nordic: ACTI) presentedpre-clinical results for the project I-3D at the annual EULAR (TheEuropean League Against Rheumatism, <a target="_blank" href="http://www.eular.org/">www.eular.org ) conference, June13-16*. "The new pre-clinical data presented show that I-3D has asignificant inhibitory effect on disease development in anexperimenta...

Ivivi's PEMF Technology Significantly Improves Neuron Survival in Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary PulsedElectromagnetic Field (PEMF) technology, developed by IviviTechnologies, Inc. (AMEX:II), improved neuron survival in astandard animal cell model of brain inflammation, researchersreported today in a platform presentation at theBioelectromagnetics Society (BEMS,http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa,...

Prana Biotechnology Presents New Key Findings on PBT2

PBT2 Alters Biomarkers and Rapidly Improves Cognition in twodistinct models of Alzheimer's Disease MELBOURNE, Australia - June 7, 2007 - Prana BiotechnologyLimited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical companyfocused on the research and development of treatments forneurodegenerative disorders, announced today that it will presentnew data on Prana's lead Alzheimer's disease (AD) d...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Theratechnologies: TH9507 Phase 3 Clinical Update

- Data from first Phase 3 trial presented at ENDO 2007 - Regulatory approvals for second Phase 3 trial open the door forpatient recruitment in Europe MONTREAL, QUEBEC -- (MARKET WIRE) -- June 04, 2007 --Theratechnologies (TSX: TH) reported today that 26-week data fromits first Phase 3 study testing TH9507 in HIV-associatedlipodystrophy were presented today in Toronto...

Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announced today positive results fromits U.S. Phase I clinical trial examining the systemicadministration of REOLYSIN(R) in patients with advanced cancers.The results indicate that REOLYSIN(R) can be delivered systemicallyto patients with advanced and metastatic cancers and causeanti-tumour activity.</p...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESSNEWSWIRE) -- Epeius Biotechnologies Corporation today announced thepublication of a historic landmark in medical oncology and adefinitive benchmark in the emerging field of cancer gene therapy.The first clinical report of its kind, Le Morte du Tumour --published in the June issue of the International Journal ofOncology, Vol.30,...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Jun 4, 2007 - Cougar Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim Phase Iand Phase II data on the Company's prostate cancer drug candidateCB7630 (abiraterone acetate) was presented at the American Societyof Clinical Oncology (ASCO) Annual Meeting, which is currentlytaking place in Chicago, Illinois. The data was presented in twoposter...

Oncolytics Biotech Inc.'s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference

CALGARY, June 01, 2007 /PRNewswire-FirstCall/ - Researchcollaborators with Oncolytics Biotech Inc. ("Oncolytics") arescheduled to deliver a poster presentation covering REOLYSIN(R)clinical trial data at the American Society of Clinical Oncology(ASCO) Annual Meeting, to be held June 1-5, 2007 in Chicago. Thedata cover final results of Oncolytics' U.K. Phase I systemicadministration trial....

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

Study released at the Pediatric Academic Societies' Annual MeetingThis Month in Toronto Shows That Switching to Masimo SET PulseOximetry Technology Can Reduce the Risk Associated with ROP by 40% IRVINE, Calif., May 30, 2007 /PRNewswire/ -- Masimo, theinventor of Pulse CO-Oximetry and Read-Through Motion and LowPerfusion pulse oximetry, reported that a new independent studypresented at the...

Generex Biotechnology Vaccine Strategy Presented at International Conference in London

WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation(NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Directorof Immunobiology at its wholly-owned Antigen Express subsidiary,has presented Antigen's vaccine development strategy at aninternational conference in London, UK. The international meeting,"Developing New Anti-Infective Agents - Challenges andOpportunities" (<a...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. reported today that data from Study 16 andStudy 17 of the Phase 2B clinical trial program evaluatingbremelanotide in men with erectile dysfunction (ED) were presentedyesterday at the American Urological Association (AUA) AnnualMeeting (AUA 2007) held in Anahe...

Inovio: DNA delivery technology shows positive human results

Inovio Biomedical’s DNA Delivery TechnologySignificantly Enhances Potency of Gene-Based Prostate CancerVaccine Key Milestone for First-in-Man DNA Vaccine Clinical Trial UsingInovio’s Electroporation DNA Delivery Technology SAN DIEGO, May 22, 2007 -- Inovio Biomedical Corp. (AMEX: INO),focused on the development of DNA-based vaccines...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase I and PhaseII data on the Company's prostate cancer drug candidate CB7630(abiraterone acetate) was presented at the American UrologicalAssociation (AUA) Annual Meeting, which is currently taking placein Anaheim, California. The data was presented by Dr. Timothy A.Yap from...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X BiotechnologiesInc. announced today that a report published in the journal Blooddemonstrated that its lead compound, obatoclax (GX15-070), inducedcell death in vitro in Mantle Cell Lymphoma (MCL) cell lines andprimary cells from 11 MCL patients. Obatoclax (GX15-070) is a smallmolecule specifically designed to inhibit all relevant members oft...

Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference

PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus InnovativeSciences, Inc. (NASDAQ:OCLS) today reported that its MicrocynTechnology was the subject of a poster presentation at the EuropeanWound Management Association (EWMA) conference that was held inGlasgow, Scotland this past week. The poster, entitled Clinical Results About an AntimicrobialSolution in the Treatment of Infected C...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. today announced plans to present the resultsfrom two bremelanotide Phase 2b studies of men with erectiledysfunction (ED). The presenters are Jed Kaminetsky, MD, ClinicalAssistant Professor, Department of Urology, NYU School of Medicine;Stanley E. Althof, PhD,...

Discovery's KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties

Discovery's KL-4 Surfactant Technology Demonstrates NovelAnti-Inflammatory Properties New Surfaxin Data Presented At the 2007 Pediatric AcademicSocieties Annual Meeting WARRINGTON, Pa., May 9, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announced that new data supportingthe anti-inflammatory properties of its novel KL-4 surfactant(lucinactant) replacement tec...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Isotechnika's Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

EDMONTON, Alberta, May 4, 2007 – Isotechnika Inc.(TSX:ISA) announced today that the Company’s lead drug,ISA247, referred to as LX211 by our partner Lux Biosciences, hasbeen selected as the subject of two presentations at theAssociation for Research in Vision and Ophthalmology (ARVO) annualmeeting, being held May 6-10 in Fort Lauderdale, Florida. The first, an o...

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ --Genelabs Technologies, Inc. announced today that a presentation wasmade today at the 20th International Conference on AntiviralResearch being held in Palm Springs, California, on anon-nucleoside hepatitis C virus (HCV) polymerase inhibitordiscovered by Genelabs. The oral presentation was given by Christopher D. Roberts,Ph...

Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTechInc. ("Quest" or the "Company") Quest is pleased to provide anupdate on the pre-clinical development of SL052 for the treatmentof prostate cancer. Prostate cancer is the second leading cause of cancer death inAmerican men with approximately 230,000 new cases and 30,000 deathspe...